

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	20525-00028	Date of first issue: 09.10.2014

SECTION 1: Identification of the substance/mixture and of the company/undertaking

: EHSDATASTEWARD@msd.com

	Product identifier Trade name	:	Peginterferon Alfa-2b Powder Formulation
1.2 R	Relevant identified uses of th	e s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture	:	Pharmaceutical
	Recommended restrictions on use	:	Not applicable
1.3 D	Details of the supplier of the s	saf	ety data sheet
	Company	:	MSD Piercetown A86 HD21 Dunboyne, Ireland
	Telephone	:	908-740-4000

1.4 Emergency telephone number

E-mail address of person

responsible for the SDS

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1B

H360FD: May damage fertility. May damage the unborn child.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms



H360FD

÷

Signal	word	

Hazard statements

May damage fertility. May damage the unborn child.



Version 3.3	Revision Date: 28.09.2024	SDS Number: 20525-00028	Date of last issue: 06.04.2024 Date of first issue: 09.10.2014
Preca	utionary statements	: Preventior P201	Obtain special instructions before use.
		P280	Wear protective gloves/ protective clothing/ eye protection/ face protection.
		Response	
		P308 + P3 ²	13 IF exposed or concerned: Get medical advice/ attention.
		Storage: P405	Store locked up.

Hazardous components which must be listed on the label:

Peginterferon Alfa-2b

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components			
Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Peginterferon Alfa-2b	215647-85-1	Repr. 1B; H360FD STOT RE 1; H372 (Gastrointestinal tract, Immune sys- tem, Cardio-vascular system, Endocrine system, Central nervous system, Liv- er, Respiratory Tract, Eve)	>= 0.3 - < 1

For explanation of abbreviations see section 16.



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	20525-00028	Date of first issue: 09.10.2014

SECTION 4: First aid measures

4.1 Description of first aid measures						
General advice	 In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice. 					
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).					
If inhaled	: If inhaled, remove to fresh air. Get medical attention.					
In case of skin contact	 In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. 					
In case of eye contact	: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.					
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.					
4.2 Most important symptoms an	nd effects, both acute and delayed					
Risks	: May damage fertility. May damage the unborn child.					
	Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.					
4.3 Indication of any immediate n	medical attention and special treatment needed					
Treatment	: Treat symptomatically and supportively.					
SECTION 5: Firefighting meas	sures					
5.1 Extinguishing media						
Suitable extinguishing media	: Water spray Alcohol-resistant foam					



Versi 3.3	ion	Revision Date: 28.09.2024		0S Number: 525-00028	Date of last issue: 06.04.2024 Date of first issue: 09.10.2014
	Unsuita media	ble extinguishing	:	None known.	
5.2 S	pecial	hazards arising from	the	substance or mi	xture
Specific hazards during fire- fighting		:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.		
	Hazard ucts	ous combustion prod-	:	Metal oxides Phosphorus compounds Oxides of phosphorus Carbon oxides	
5.3 A	dvice	or firefighters			
Ş		protective equipment	:	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.	
	Specific ods	extinguishing meth-	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to c so. Evacuate area.	

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	nal precautions : Use personal		Use personal protective equipment.
			Follow safe handling advice (see section 7) and personal pro-
			tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so.
	Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up	:	Sweep up or vacuum up spillage and collect in suitable con- tainer for disposal.
		Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
		Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are re-
		leased into the atmosphere in sufficient concentration.
		Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items



Versior 3.3	Revision Date: 28.09.2024	SDS Number: 20525-00028	Date of last issue: 06.04.2024 Date of first issue: 09.10.2014
		mine which regu Sections 13 and	cleanup of releases. You will need to deter- lations are applicable. 15 of this SDS provide information regarding ational requirements.
	erence to other sections ctions: 7, 8, 11, 12 and 13.		
SECTI	ON 7: Handling and sto	orage	
7.1 Pre	cautions for safe handlin	g	
Te	chnical measures	causing an explo Provide adequat	may accumulate and ignite suspended dust osion. e precautions, such as electrical grounding inert atmospheres.
Lo	cal/Total ventilation		ation is unavailable, use with local exhaust
	lvice on safe handling	 practice, based of sessment Keep container to Minimize dust get Keep container of Keep away from Take precautions Take precautions Take care to pre environment. If exposure to char flushing systems 	lust. th eyes. lance with good industrial hygiene and safety on the results of the workplace exposure as-
7200	nditions for safe storage,	nated clothing be	
	equirements for storage	• •	labelled containers. Store locked up. Keep
	eas and containers		ore in accordance with the particular national
Ac	lvice on common storage	Strong oxidizing	stances and mixtures
7.3 Spe	ecific end use(s)		
-	ecific use(s)	: No data available	9



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	20525-00028	Date of first issue: 09.10.2014

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

dusts non-specific

4 mg/m3 Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable dust) Basis: IE OEL

10 mg/m3 Value type (Form of exposure): OELV - 8 hrs (TWA) (inhalable dust) Basis: IE OEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Sucrose	57-50-1	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL
		OELV - 15 min (STEL)	20 mg/m3	IE OEL
Peginterferon Alfa- 2b	215647-85- 1	TWA (inhalable fraction)	0.2 μg/m3 (OEB 5)	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health ef-	Value
			fects	
Disodium hy- drogenorthophos- phate	Workers	Inhalation	Long-term systemic effects	4.07 mg/m3
	Consumers	Inhalation	Long-term systemic effects	3.04 mg/m3

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value	
Disodium hydrogenorthophos-	Fresh water	0.05 mg/l	
phate			
	Marine water	0.005 mg/l	
	Intermittent use/release	0.5 mg/l	
	Sewage treatment plant	50 mg/l	

8.2 Exposure controls

Engineering measures

Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment



Version 3.3	Revision Date: 28.09.2024		S Number: 525-00028	Date of last issue: 06.04.2024 Date of first issue: 09.10.2014	
·	Eye/face protection		Wear the following personal protective equipment: Safety goggles Equipment should conform to I.S. EN 166		
Han	d protection				
Ν	<i>l</i> aterial	:	Chemical-resistant gloves		
F	Remarks		Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous sub- stance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.		
Skin	and body protection	:	resistance data ar potential. Skin contact must	e protective clothing based on chemical nd an assessment of the local exposure be avoided by using impervious protective aprons, boots, etc).	
Res	piratory protection	:	If adequate local e sure assessment ommended guide	exhaust ventilation is not available or expo- demonstrates exposures outside the rec- lines, use respiratory protection. I conform to I.S. EN 143	
F	filter type	:	Particulates type		

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	powder
Colour	:	White to light yellow
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han- dling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower	:	No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Peginterferon Alfa-2b Powder Formulation

Ver 3.3	sion	Revision Date: 28.09.2024		S Number: 525-00028	Date of last issue: 06.04.2024 Date of first issue: 09.10.2014
	flamma	ability limit			
	Flash p	point	:	No data available	9
	Auto-ig	nition temperature	:	No data available	9
	Decom	position temperature	:	No data available	9
	рН		:	No data available	9
	Viscosi Visc	ity cosity, dynamic	:	No data available	9
	Viso	cosity, kinematic	:	No data available	9
	Solubil Wat	ity(ies) ter solubility	:	No data available	2
	Partitio octano	n coefficient: n- I/water	:	No data available	2
	Vapou	r pressure	:	No data available	9
	Density	/	:	1 g/cm ³	
	Relativ	e vapour density	:	No data available	9
		e characteristics ticle size	:	No data available	9
9.2		nformation			
	Explos		:	Not explosive	
	Oxidizi	ng properties	:	The substance o	r mixture is not classified as oxidizing.
	Evapor	ration rate	:	No data available	9
	Molecu	ılar weight	:	No data available	9

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions

: May form explosive dust-air mixture during processing, han-



Version 3.3	Revision Date: 28.09.2024	SDS Number: 20525-00028	Date of last issue: 06.04.2024 Date of first issue: 09.10.2014
		dling or othe Can react w	er means. ith strong oxidizing agents.
	ditions to avoid litions to avoid	: Heat, flames Avoid dust f	s and sparks. ormation.
	mpatible materials rials to avoid	: Oxidizing ag	gents
	ardous decomposition azardous decomposition	-	wn.
SECTIO	N 11: Toxicological	information	
11.1 Infor	mation on hazard cla	sses as defined in	Regulation (EC) No 1272/2008
Inforr expo	nation on likely routes sure	of : Inhalation Skin contact Ingestion Eye contact	
	e toxicity classified based on ava	ilable information.	
<u>Com</u>	ponents:		
Pegi	nterferon Alfa-2b:		
	e toxicity (other routes nistration)		> 20.1 mg/kg Route: Intravenous
		LD50 (Monke	ey): > 9.8 mg/kg
-	corrosion/irritation lassified based on ava	ilable information.	
<u>Com</u>	ponents:		
Pegi Spec Resu		: Rabbit : Mild skin irrit	ation
1.030	in c		
	ous eye damage/eye i classified based on ava		
<u>Com</u>	ponents:		
-	nterferon Alfa-2b:		
Snoo	ion	· Pabbit	

Species	:	Rabbit
Result	:	Mild eye irritation



on

Peginterferon Alfa-2b Powder Formulation

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 06.04.2024
3.3		20525-00028	Date of first issue: 09.10.2014

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Components:

Peginterferon Alfa-2b:

Genotoxicity in vitro	:	Test Type: reverse mutation assay Result: negative
		Test Type: Chromosomal aberration Test system: Human lymphocytes Result: negative
Genotoxicity in vivo	:	Test Type: In vivo micronucleus test Species: Mouse Result: negative

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:

Peginterferon Alfa-2b:

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Monkey, female Application Route: Subcutaneous Dose: 0.35 milligram per kilogram Symptoms: Effect on estrous cycle
Reproductive toxicity - As- sessment	:	Clear evidence of adverse effects on development, based o animal experiments., Clear evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:

Peginterferon Alfa-2b:

Target Organs

: Gastrointestinal tract, Immune system, Cardio-vascular sys-

Commission Regulation (EU) 2020/878



Peginterferon Alfa-2b Powder Formulation

Vers 3.3	sion	Revision Date: 28.09.2024		DS Number: 525-00028	Date of last issue: 06.04.2024 Date of first issue: 09.10.2014
Assessment		:	piratory Tract, Ey	vstem, Central nervous system, Liver, Res- e to organs through prolonged or repeated	
	Repea	ted dose toxicity			
	Compo	onents:			
	Pegint	erferon Alfa-2b:			
			:	Mouse 0.0038 mg/kg Subcutaneous 9 d	
			:	Rat 0.0042 mg/kg Subcutaneous 30 d	
	Exposi	s - ation Route ure time Organs	:	Monkey 0.12 mg/kg Subcutaneous 30 d Blood, Bone marr	ow, Immune system
		L		Monkey 0.015 mg/kg 0.077 mg/kg 3 Months Respiratory Tract system, Bone ma	, Cardio-vascular system, Central nervous rrow

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Peginterferon Alfa-2b:



Version 3.3	Revision Date: 28.09.2024		DS Number: 0525-00028	Date of last issue: 06.04.2024 Date of first issue: 09.10.2014
Inhala	ation	:	Symptoms: flu-lik mental depressio	e symptoms, Gastrointestinal disturbance, n, tingling
SECTION	I 12: Ecological infor	ma	ntion	
12.1 Toxic	city			
Comp	ponents:			
Pegin	terferon Alfa-2b:			
	exicology Assessment	:	No data available	
Chror	nic aquatic toxicity	:	No data available	
12.2 Persi	stence and degradabil	ity		
Com	oonents:			
-	nterferon Alfa-2b: gradability	:	Result: Readily b Biodegradation: Exposure time: 2 Method: OECD T	63 %
	ccumulative potential ata available			
12.4 Mobi No da	lity in soil Ita available			
12.5 Resu	Its of PBT and vPvB as	sse	ssment	
Produ	uct:			
Asses	ssment	:	to be either persis	hixture contains no components considered stent, bioaccumulative and toxic (PBT), or nd very bioaccumulative (vPvB) at levels of
12.6 Endo	crine disrupting prope	ertie	es	
Produ	uct:			
Asses	ssment	:	ered to have end REACH Article 57	ixture does not contain components consid- ocrine disrupting properties according to 7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.
12.7 Other	r adverse effects			
No da	ta available			



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	20525-00028	Date of first issue: 09.10.2014

SECTION 13: Disposal considerations

13.1 Waste treatment methods	
Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	 Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.2 UN proper shipping name		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.3 Transport hazard class(es)		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.4 Packing group		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good



Version 3.3	Revision Date: 28.09.2024	SDS Number: 20525-00028	Date of last issue: 06.04.2024 Date of first issue: 09.10.2014		
	Cargo) Passenger)	0	d as a dangerous good d as a dangerous good		
14.5 Enviro	ponmental hazards gulated as a dangerous	Ũ			
14.6 Special precautions for user Not applicable					
14.7 Maritii Remar	me transport in bulk a ks	0) instruments le for product as supplied.		

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing of the market and use of certain dangerous substance mixtures and articles (Annex XVII)		Not applicable
REACH - Candidate List of Substances of Very High	n :	Not applicable
Concern for Authorisation (Article 59).		
Regulation (EC) on substances that deplete the ozo	one :	Not applicable
layer		
Regulation (EU) 2019/1021 on persistent organic po	ollu- :	Not applicable
tants (recast)		
Regulation (EU) No 649/2012 of the European Parli		Not applicable
ment and the Council concerning the export and imp	oort	
of dangerous chemicals		
REACH - List of substances subject to authorisation	n :	Not applicable
(Annex XIV)		
Source III: Directive 2012/19/ELL of the European D	orliamont	and of the Council

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.



Versio 3.3	n Revision Date: 28.09.2024		OS Number: 525-00028	Date of last issue: 06.04.2024 Date of first issue: 09.10.2014				
SECT	SECTION 16: Other information							
Other information :		Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.						
Full text of H-Statements								
H360FD : H372 :		May damage fertility. May damage the unborn child. Causes damage to organs through prolonged or repeated exposure.						
F	Full text of other abbreviations							
S	epr. TOT RE : OEL	:	Ireland. List of Ch	city gan toxicity - repeated exposure emical Agents and Carcinogens with Occu- e Limit Values - Code of Practice, Schedule 1				
IE	OEL / OELV - 8 hrs (TWA) OEL / OELV - 15 min STEL)	:	Occupational exp	osure limit value (8-hour reference period) osure limit value (15-minute reference peri-				

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA



Classification procedure:

Peginterferon Alfa-2b Powder Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	20525-00028	Date of first issue: 09.10.2014

- Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data		eChem Portal search results and European Chemicals Agen-
Sheet		cy, http://echa.europa.eu/

Classification of the mixture:

		•
Repr. 1B	H360FD	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN